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Abstract Purpose: Early diagnosis of cancer is crucial for the success of treatment of the disease, and
there is a need for markers whose differential expression between disease and normal tissue
could be used as a diagnostic tool. Spontaneously occurring malignancies in pets provide a
logical tool for translational research for human oncology. Lymphoma, one of the most common
neoplasms in dogs, is similar to human non ^Hodgkin’s lymphoma and could serve as an experi-
mental model system.
Experimental Design: Thirteen lymph nodes from normal dogs and11lymph nodes from dogs
with B-cell lymphoma were subjected to proteomic analysis using two-dimensional PAGE
separation and matrix-assisted laser desorption/ionization time-of-flight analysis.
Results: A total of 93 differentially expressed spots was subjected to matrix-assisted laser
desorption/ionization time-of-flight tandem mass spectrometry analysis, and several proteins
that showed differential expression were identified. Of these, prolidase (proline dipeptidase),
triosephosphate isomerase, and glutathione S-transferase were down-regulated in lymphoma
samples, whereas macrophage capping protein was up-regulated in the lymphoma samples.
Conclusions: These proteins represent potential markers for the diagnosis of lymphoma and
should be further investigated in human samples for validation of their utility as diagnostic
markers.
Spontaneously occurring malignancies in pets provide a
logical tool for translational research in human oncology
(1). Companion animals are exposed to similar environmental
conditions and carcinogens as humans. For example, similar
genetic changes leading to cancer have been found in dogs
and humans as in the case of renal cancer (2–4). The
completely sequenced dog genome is predicted to contain
19,300 protein-coding genes and nearly all are homologues of
human genes (5). However, little work has been done to date
on using this useful system for identifying molecular markers
for cancer.
Lymphoma is one of the most common neoplasms in dogs
and is similar to human non–Hodgkin’s lymphoma. In dogs,
the multicentric form involving peripheral lymph nodes is the
most common form, but disease can arise from any tissue. As
with non–Hodgkin’s lymphoma, canine lymphoma can be
either B or T cell, but most of the peripheral lymphomas are B
cell (6). Canine lymphoma has a reported annual incidence of
25 of 100,000 dogs per year and accounts for 5% of all
malignant neoplasms in the dog (6). In humans, the B-cell
lymphoid neoplasm incidence is reported to be 26 of 100,000
per year (7). Canine non–Hodgkin’s lymphoma is comparable
clinically and histologically with intermediate and high-grade
non–Hodgkin’s lymphoma in humans (1, 8). It is a reasonable
model for comparison with human non–Hodgkin’s lympho-
ma as it is a common, nonviral-associated, spontaneous tumor.
Canine lymphoma is advantageous for study compared with
humans in that average remission times are shorter than 1 year,
thus facilitating rapid accrual of data. Surgical removal of
affected lymph nodes and histopathologic analysis are a
routine part of therapy, and canine lymphoma is treated with
the same drugs as human lymphoma, most commonly
vincristine, cyclophosphamide, L-asparaginase, doxorubicin,
and prednisone (9). These considerations, taken together with
the availability of samples, make the dog an excellent candidate
for proteomic-based research on cancer.
Proteomics is one of a variety of approaches that are currently
in use for the identification of the molecular changes that
accompany the progression of neoplastic disease. It is now
widely used and strongly complements gene expression
approaches (10) but has not previously been used to study
canine cancer. Proteomic approaches have the advantage that
they can identify changes in protein isoforms and posttransla-
tional modifications that are common in cancer and go
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undetected by microarray analyses of RNA expression. In the
following study, we report the results of a comparative
proteomic analysis of 13 lymph nodes from normal dogs and
11 lymph nodes from dogs with B-cell lymphoma and the
identification of several differentially expressed protein markers.
Materials andMethods
Animals. The experimental protocol for the nondiseased control
dogs was approved by the University of Missouri-Columbia Animal
Care and Use Committee, and the dogs were obtained through the
Office of Animal Resources. Five mature, male, nonconditioned,
random source, mixed breed dogs were obtained. The dogs appeared
healthy based on physical examination. On arrival to our facility, the
dogs were anesthetized with sodium pentobarbital and lymph nodes
were removed. In accordance with the approved protocol, the dogs were
euthanatized immediately after the removal of the lymph nodes and
before recovery from anesthesia. Euthanasia was accomplished by the
use of pentobarbital sodium (Vortech, Dearborn, MI). In each case, we
removed the superficial, peripheral, lymph nodes (prescapular and
popliteal) because these are most often removed for biopsy in
lymphoma cases. A portion of each lymph node was submitted for
histopathology and no lymphoma cells were detected in these samples.
Eleven dogs with lymphoma were client-owned animals presented to
the University of Missouri-Columbia Veterinary Medical Teaching
Hospital for diagnosis and treatment of suspected lymphoma. Written
permission for removal of a lymph node and inclusion in this study was
obtained from the owners. One affected peripheral lymph node was
obtained from each dog before any chemotherapy was given.
Histopathologic examination determined that all of these dogs had B-
cell lymphoma. There were seven male and four female dogs. Seven
dogs were mixed breed. Of the purebred dogs, there was one each of the
following breeds: Newfoundland, Dalmatian, Pembroke Welsh corgi,
and Australian shepherd.
Lymph node preparation. All lymph nodes were aseptically removed
under general anesthesia. A portion of the node was placed in formalin
for the purpose of histopathologic evaluation. The nodes with
lymphoma were also submitted for immunophenotyping to determine
B-cell or T-cell phenotype. The remainder of the lymph node was
prepared for proteomic analysis. The lymph node was trimmed to
remove the capsule, connective tissue, and adipose tissue; rinsed with
saline; placed in a cryogenic tube; frozen in liquid nitrogen; and stored at
80jC until processed.
Protein solubilization. The protocol for sample solubilization was
arrived at empirically to obtain the highest recovery of protein. Sample
weight was recorded, and the tissue was ground in dry ice with mortar
and pestle. The ground sample and dry ice were placed in a tube and
put in 80jC freezer where the dry ice evaporated. Lysis buffer [0.175
mol/L Tris-HCl (pH 8.8), 5% SDS, 15% glycerol, 0.3 mol/L DTT] was
added to the frozen samples. Lysis buffer (5 mL) was added to samples
with a weight of <250 mg (and an additional 1 mL for each additional
70 mg of tissue). The sample was further solubilized by vortexing,
pipetting, and sonication. The insoluble portion was removed by
centrifugation in a refrigerated Jouan model CR412 (Jouan, Inc.,
Winchester, VA) tabletop centrifuge at 1,700  g for 10 min at 4jC. The
supernatant was moved to a glass tube followed by precipitation of
the protein with 4 volumes of ice-cold acetone for 1 h at 20jC. The
samples were then centrifuged in a Beckman J2-21 centrifuge
(Fullerton, CA) at 9,000  g for 20 min at 0jC. The supernatant
was discarded and the pellets were rinsed twice in 15 mL of cold 80%
acetone with mechanical disruption of the pellet by pipetting,
vortexing, and sonication. The protein precipitates were then air dried
and solubilized in a solution of 8 mol/L urea, 2 mol/L thiourea, 2%
CHAPS, 0.2% Triton X-100, 50 mmol/L DTT, and 0.5% ampholytes
(pH 3-10) at a volume of 6.5 AL/mg of original tissue. The samples
were incubated for 1 h at room temperature, 25 mmol/L iodoaceta-
mide was added to acetylate all free SH groups, and the samples
were centrifuged for 30 min in a Beckman TL-100 centrifuge at
150,000  g at 4jC. The supernatant was removed to clean tubes, and
protein concentration of the sample was determined using bicincho-
ninic acid protein determination assay (Pierce, Rockford, IL).
Protein separation. Two-dimensional SDS-PAGE was used to sepa-
rate lymph node proteins. Immobilized pH gradient strips (11 cm) with
a pH range of 4 to 7 or 5 to 8 (Proteome Systems Ltd., Boston, MA) were
used for the first-dimension separation. The strips were rehydrated with
1.5 mg protein for 20 to 22 h. The proteins were focused for 17 h on an
Fig. 1. Two-dimensional gel analyses of
proteins from normal and lymphoma canine
lymph nodes. Lymph nodes were harvested
and proteins were solubilized according
to the procedure detailed in Materials and
Methods.The proteins were separated by
first-dimension pI on either pH 4 to 7 or pH
5 to 8 immobilized pH gradient strips
followed by second-dimension separation
by SDS-PAGE.The figure shows
representative gels and molecular weight
standards (MW), which were run on each
gel.The gels display the high resolution,
which was typical of all the gels.
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ElectrophoretIQ 2000 system (Proteome Systems). The voltage was
steadily increased from 100 to 10,000 V over 8 h, maintained for an
additional 8 h, and then decreased to 2,500 V over 1 h. The immobilized
pH gradient strips were removed and equilibrated with two changes of a
solution of 6 mol/L urea, 5% SDS, and 50 mmol/L Tris-acetate (pH 7.0)
for 10 min. The second-dimension separation of proteins was done
immediately using precast 8% to 18% SDS-PAGE gels (Proteome
Systems). Multiple gels were electrophoresed at the same time using
the Proteome Systems ElectrophoretIQ 2000 system at 50 mA per gel for
1.5 h. The gels were then stained for 12 h with colloidal Coomassie blue
(11) and destained in 1% acetic acid for 2 h.
Gel evaluation. The gels were scanned using a flat bed scanner (Epson
Expression 1680, Nagano, Japan). The protein separation patterns were
examined visually, and each lymphoma lymph node gel was compared
with each normal lymph node gel. The molecular weight markers were
from Proteome Systems, and the empirical molecular weights of the
separated proteins were estimated to the nearest thousand kDa.
Protein identification. Gel plugs containing spots of interest were
excised and destained thrice with 50% acetonitrile and 50 mmol/L
ammonium bicarbonate. Trypsin digestion was done by incubating the
gel plugs with trypsin for 5 h at 4jC followed by replacing the trypsin
solution with 30 AL of 50 mmol/L ammonium bicarbonate and
continued digestion at 37jC for 18 h. Peptides were extracted from gel
pieces twice with 60% acetonitrile and 0.3% trifluoroacetic acid.
Recovered peptides were dried in a centrifugal evaporator and
resuspended in 15 AL of 1% formic acid and processed using ZIP tips
(Millipore, Billerica, CA). Peptides were eluted from the ZIP tips in 4 AL
of 70% acetonitrile and 1% formic acid, and 1.0 AL was spotted onto the
matrix-assisted laser desorption/ionization (MALDI) target. Spectra were
acquired on an Applied Biosystems 4700 Proteomics Analyzer MALDI
tandem time-of-flight mass spectrometer (MS) operated using 4000
Series Explorer software V3.0 in positive ion reflector mode. Instrument
calibration in MS mode was achieved using 4700 calibration mixture
(Applied Biosystems, Foster City, CA) spotted on six peripheral
calibration spots on the MALDI target. Instrument calibration in MS/
MS mode was achieved using the [Glu1]fibrinopeptide B standard
(1,570.7 Da) in each of six calibration spots. Sample spectra were
acquired in MS mode over a mass range of 800 to 4,000 Da. MS/MS
fragmentation spectra of the 10 most abundant peptides (excluding
trypsin autolysis peptides) were automatically acquired from each
sample. Using default calibration of sample spots, the average mass
error (determined by masses of trypsin autolysis ions present in the
spectra) ranged from 18.28 ppm in the first sample acquired to 45.35
ppm in the last acquired sample.
Informatics. Searches were conducted with a FASTA-formatted
database of DOG gene open reading frames (downloaded from the
National Center for Biotechnology Information 03242006 and indexed
for use by MASCOT server version 2.1). The canine database was
searched using GPS Explorer software V3.0, which is integrated with the
MASCOT search engine. A ‘‘combined MS + MS/MS’’ search was
conducted that includes a peptide mass fingerprinting approach to
protein identification supplemented with MS/MS ion searches of those
peptides acquired from the sample. Search variables for DOG FASTA
database: monoisotopic peaks only, filtering mass range of 800 to 4,000
Da, minimum s/n ratio of 10, ‘‘common’’ trypsin autolysis ions within a
mass tolerance of 75 ppm were removed from the spectra before the
database search, density filter of 50 peaks per 200 Da, and maximum of
100 peaks per spectrum. Database search criteria included one allowed
miscleavage, carbamidomethyl fixed modification, methionine oxida-
tion and deamidation of N and Q, precursor mass tolerance of 75 ppm,
MS/MS fragment tolerance of 0.05 Da, minimum two identified
peptides, and minimum ion score confidence interval of 85%.
Statistical methods. Fisher’s exact test was used for determining the
significance of the differential expression of a protein in the normal and
lymphoma samples. Statistical calculations were done with the
computer-based software SigmaStat for Windows version 3.10 (Systat
Software, Inc., Richmond, CA). Significance was set at P < 0.05.
Results
Participating animals. The participating animals were first
screened for the presence and type of the disease. None of the
nondiseased dog samples had evidence of lymphoma. All the
lymphoma samples were found to be B-cell phenotype based on
Fig. 2. Differential expression of proteins between normal (noncancerous) and
lymphoma lymph nodes. Comparisons of representative gels showing the
differential expression of proteins identified in this study. Black arrow, spot presence
(or absence).Vertical arrowhead, pHor pI. Horizontal arrowhead, molecular weight
(mw) of each spot. (A) Equal expression of a protein is depicted. In (C), (D), and
(E), there is a differential expression of the protein, whereas in (B) there is a
complete absence in the lymphoma sample.
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CD79-positive reaction. The lymphomas were classified using
the NIH working formulation and composed of diffuse small
cleaved cell lymphoma, diffuse large cleaved cell lymphoma,
diffuse large noncleaved cell lymphoma, and diffuse mixed cell
lymphoma (1). The limited numbers of each tumor type
prevented any meaningful correlation with the proteomic data.
Sample preparation and gel evaluation. Standard, commer-
cially available lysis buffers resulted in gels of poor quality, and
the sample solubilization procedure described in Materials and
Methods was developed. The proteins were then separated by
two-dimensional PAGE using a pH range of either 5 to 8 or 4 to 7
for the first dimension and 8% to 18% SDS-PAGE gels for the
second dimension. This method of sample preparation resulted
in gels that had reproducibly high resolution as is shown in Fig. 1.
The gels were scanned as described and visually examined.
Each lymphoma lymph node gel was compared with each
normal lymph node gel. Any differences in protein expression
between the compared gels were noted. Examples of four of
these differentially expressed spots are depicted in Fig. 2.
Twenty-one protein spots were identified as having differences
in expression between nonlymphomas and lymphomas. In
some cases, the proteins showed higher expression in the
lymphoma lymph nodes compared with nonlymphoma lymph
nodes, and in other cases, the opposite was observed. Seventeen
of these differentially expressed spots were seen on the pH 5 to
8 gels (Table 1) and four protein spots were seen on the pH 4 to
7 gels (Table 2). Several randomly selected samples represent-
ing the differentially regulated proteins were removed from the
gels for protein identification by MALDI time-of-flight MS
(noted with an asterisk in Tables 1 and 2). The distribution of
the protein spots in the normal versus lymphoma samples is
shown with respect to either the total number of samples or the
number of samples that had that spot (Table 3). The latter ratio
is important because it highlights the bias, and thus the
predictive value, of the protein for either the normal or
lymphoma samples.
Protein identification. To test the reproducibility of the
approach, we analyzed two proteins: one that appeared in all
the normal and lymphoma pH 5 to 8 gels and the other
appeared on all the pH 4 to 7 gels. From the pH 5 to 8 gels, the
spots had an observed molecular weight of 45,000 and an
isoelectric focusing (pI) of 7.3. Seven spots (three from normal
lymph node gels and four from lymphoma) were picked for
analysis. Six of the seven were identified as a-enolase, an
Table 1. Summary of two-dimensional electrophoretic analysis of proteins from noncancerous and lymphoma
lymph nodes
Sample/
gel
Protein spot no.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 C
N * * * * *
N * * * * *
N * *
N * * *
N
N * * * *
N *
N * * *
N * * * *
N * *
N * * * *
N * * *
N
L * * *
L * * * *
L *
L *
L * * * *
L * * * *
L * * * * *
L * * * *
L * * * *
L *
L * * *
NOTE: pI at pH 5 to 8. Shaded boxes indicate the presence of a protein spot. *, spot excised for MALDI time-of-flight analysis.
Abbreviations: N, noncancerous; L, lymphoma; C, control.
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abundant cytosolic protein with a predicted molecular weight
of 49,500 (Fig. 2A and ‘‘control’’ lane in Table 1). From the pH
4 to 7 gels, three spots (two normal and one lymphoma) were
picked for analysis with a molecular weight of 16,000 and a pI
of 6.7 (Table 2, control lane). Two of the three were identified
as superoxide dismutase, whereas the other spot gave no
identification. Overall, this underscored the reproducibility of
the gels and suggested that the approach of spot evaluation and
identification had worked well.
Of the 21 proteins that were expressed differentially between
cancerous and noncancerous lymph nodes, 4 gave consistent
identification of the spots picked for analysis (Table 4). No
consensus of identification was found with the others, which is
most likely due to low protein levels and/or overlapping of
multiple proteins in the gel.
(a) A protein with an observed molecular weight of 24 kDa
and a pI of 7.9 was present in 9 of 13 gels from normal lymph
nodes but only in 1 of 11 gels of the lymphoma samples
(Fig. 2B; Table 1, spot no. 4). The difference was significant
(P = 0.005). In three of four representative analyzed spots, it
was identified as triosephosphate isomerase, a glycolytic
enzyme. It functions in catalyzing the interconversion of
glyceraldehyde-3-phosphate and dihydroxyacetone phosphate.
Triosephosphate isomerase is necessary for efficient energy
production, is important in several metabolic pathways, and is
present in the cytoplasm of all tissues (12). An inherited
deficiency occurs in humans and causes a rise in dihydroxyac-
etone phosphate. Clinical signs are hemolytic anemia, early
death, and neurodegeneration (13).
(b) A protein with observed molecular weight of 55 kDa and
pI of 6.1 was found in 8 of 13 of the normal samples and in
none of the lymphoma samples (Fig. 2C; Table 1, spot no. 7).
The difference was significant (P = 0.006). Four representative
spots were analyzed, and three resulted in the identification of
Xaa-Pro dipeptidase (prolidase). Prolidase is a 492-amino acid
(54.5 kDa) manganese metalloenzyme, which catalyzes the
release of any NH2-terminal amino acid adjacent to a proline
residue. The enzyme splits dipeptides with a prolyl residue in
the COOH-terminal position. Bacterial aminopeptidases P II
(gene pepP) and proline dipeptidase (gene pepQ), yeast
hypothetical proteins YER078c and YFR006w, Mycobacterium
tuberculosis hypothetical protein MtCY49.29c, and human
proline dipeptidase (gene PEPD) are evolutionary related.
Proline peptidase plays an important role in collagen metab-
olism because of the high level of iminoacids in collagen. The
released proline is used for the production of collagen (14).
Prolidase has high enzyme activity in the intestinal mucosa,
kidney, and erythrocytes. Liver, brain, heart, uterus, thymus,
leukocytes, and skin fibroblasts also contain prolidase (14).
(c) A protein with an observed molecular weight of 36 kDa
and a pI of 6.4 was found in 6 of 11 of the lymphoma samples
and in 3 of 13 normal gels (Fig. 2D; Table 1, spot no. 16). The
difference was not significant (P = 0.206). In three of three
representative analyzed spots, it was identified as macrophage
capping protein, a 348-amino acid (38.5 kDa) calcium-
sensitive protein. Interestingly, a second group of protein spots
at molecular weight of 29 kDa and a pI of 6.7 (Table 1, spot no.
13), which also was primarily lymphoma associated (5 of the
11 lymphoma gels and 0 of 13 normal gels), was also identified
as macrophage capping protein in three of the five spots
analyzed. The difference was significant (P = 0.011). This group
of spots could possibly represent a processing product of the
protein, but more extensive analysis is needed to answer this
question. Macrophage capping protein, along with gelsolin,
villin, adseverin, advillin, and supervillin, is a member of the
gelsolin protein family (15). These proteins cap the barbed
ends of actin filaments that are necessary for regulating actin-
based motility in nonmuscle cells. Macrophage capping protein
was first isolated from alveolar macrophages (16). The levels
are highest in macrophages where it is a major stimulator of
macrophage phagocytosis (17). Detection of macrophage
capping protein in other tissues is variable, with one report
suggesting presence in lung, kidney, and smaller amounts in
the heart, whereas another study found macrophage capping
protein in the spleen (18, 19). A third study suggests more
widespread presence, including skeletal muscle, stomach,
spleen, kidney, heart, lung, intestine, and uterus (20).
(d) A protein spot with an observed molecular weight of 24
kDa and a pI of 7.0 was observed in 11 of 13 normal lymph
nodes and in only 3 of 11 gels of lymphoma samples (Fig. 2E;
Table 1, spot no. 2). The difference was significant (P = 0.011).
In three of four representative spots analyzed from the normal
gels, it was identified as glutathione S-transferase-P (GST-P;
GST7-7). GST-P is one of the five soluble cytosolic GST
isoenzymes that are each a distinct gene product. The enzymes
transfer reduced glutathione to a broad range of genotoxins to
Table 2. Summary of two-dimensional
electrophoretic analysis of proteins from
noncancerous and lymphoma lymph nodes
Sample 18 19 20 21 C
N
N
N
N
N * *
N * *
N
N *
N * *
N * * *
N
N
L
L
L * *
L *
L *
L *
L * *
L
L *
L * *
NOTE: pI at pH 4 to 7. Shaded boxes indicate the presence of a
protein spot. *, spot excised for MALDI time-of-flight analysis.
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detoxify them and facilitate their removal from cells. These
enzymes are widely expressed in tissues, and their expression is
up-regulated on cell exposure to genotoxins. The enzymes are
generally believed to protect cells from carcinogens (21).
Discussion
The goals of cancer research include a better understanding of
the development of cancer cells and their interactions with
normal cells. To this end, it has been productive to identify
cellular and biochemical differences between normal and tumor
cells. Modern system approaches to this problem include using
microarray analysis to determine differences in mRNA levels
and gene methylation patterns between normal and cancer cells
or proteomic analysis to directly detect changes in protein
expression and/or posttranslational modifications (e.g., phos-
phorylation, glycosylation, lipidation, and peptide cleavage) in
the cancer cell (22, 23). We applied this latter approach to study
the differences between the proteomes of cancerous and
noncancerous lymph nodes of dogs. Canine lymphoma is an
attractive translational model for human cancer because it is a
common nonviral-associated spontaneous neoplasm in dogs
and is similar to human non–Hodgkin’s lymphoma. Canine
lymphoma is treated with the same drugs as human lymphoma,
most commonly vincristine, cyclophosphamide, L-asparaginase,
doxorubicin, and prednisone (9), and taken together with the
availability of samples, these considerations make the dog an
excellent candidate for proteomic-based research on cancer.
In this study, significant differences in protein expression
were detected between the lymph nodes of normal dogs and
those with B-cell lymphoma. In some instances, there was a
differential up-regulation or down-regulation. In many cases, a
protein was not limited exclusively to either normal of
cancerous lymph nodes. We believe that our experimental
approach facilitated these findings. Previous strategies have
often used a reference gel that is composed of all the spots
present on gels from multiple samples of normal cells or
tissues. The reference gel was then used to compare spots
present on the gels from the diseased tissue. Thus, in order for a
particular protein in a diseased sample to be recognized as
uniquely present or absent, it could not have been present on
any of the normal gels. However, there are many genetic,
physiologic, and environmental differences between animals
that complicate this approach. As cancer progresses, the protein
profile will gradually change, and each individual can display
a different pattern of change, with the proteome of some
nondisease-appearing animals containing the proteins of
diseased individuals and vice versa. For lymph nodes, it is
reasonable to assume that the protein profile of a particular
node is directly dependent on what is happening in the tissues
that drain to that lymph node, and as such, the lymph nodes
from different animals could have different proteomes. Based
on these considerations, our approach was to systematically
compare each lymphoma sample to each nondiseased sample
and then record the protein spots that differ in each set,
assuming that there is not an absolute difference between the
protein profiles of normal and diseased tissue. Indeed, a similar
result was seen in previous proteomic analyses of other cancers
(24, 25). Overall, this supports the idea that multiple markers
will be needed for accurate cancer diagnosis, and ultimately,
markers discovered in different studies will probably be used
together for diagnosis and staging. The current study in dogs
identified four candidates as markers for lymphoma.
Prolidase was found to be expressed in some normal but not
lymphoma samples. As an iminopeptidase enzyme, prolidase is
necessary for protein catabolism or processing. An inherited
Table 3. Occurrence of protein spots in noncancerous versus lymphoma samples
Protein
spot no.
Samples with
protein spot
present (%)
Noncancerous
samples with
protein spot present
(% of total samples)
Lymphoma
samples with
protein spot present
(% of total samples)
Noncancerous
samples in
total positive
samples (%)
Lymphoma
samples in
total positive
samples (%)
1 63 50 13 80 20
2 63 50 13 80 20
3 42 42 0 100 0
4 42 38 4 90 10
5 42 38 4 90 10
6 59 38 21 64 36
7 33 33 0 100 0
8 33 29 4 88 13
9 50 29 21 58 42
10 25 25 0 100 0
11 4 0 4 0 100
12 13 0 13 0 100
13 21 0 21 0 100
14 25 4 21 17 83
15 25 0 25 0 100
16 38 13 25 33 67
17 46 17 29 36 64
18 73 50 23 69 31
19 64 41 23 64 36
20 73 41 32 56 44
21 81 36 45 44 56
NOTE: Isoelectric focusing pH 5-8 (spots 1-17) and pH 4-7 (spots 18-21).
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autosomal recessive deficiency of prolidase enzyme activity has
been reported in humans and presents with variable symptoms,
such as chronic recurrent infections, splenomegaly, skin lesions,
and mental retardation (14). In contrast, decreased prolidase
expression, without a general decrease, has been found in diseased
pancreatic tissue. A 2-fold decrease in prolidase activity compared
with normal tissuewas seen in pancreatitis, and a 10-fold decrease
was found in pancreatic cancer tissue (26). Prolidase activity has
also been shown to be reduced in human MCF-7 breast cancer
cells when compared with normal human fibroblasts (27). The
significance of reduced prolidase in cancerous tissue is unknown
(27). The lack of prolidase in the lymphoma samples in this
study agrees with previous study of cancer tissues. It should be
stressed that our results do not imply that it was totally absent
but rather reduced to below the level of detection.
Macrophage capping protein was found primarily in lym-
phoma samples. It is a member of the gelsolin family, which are
proteins that bind actin. Included in this family are gelsolin,
villin, adseverin, macrophage capping protein, advillin, and
supervillin. Unlike other members, macrophage capping pro-
tein binds but does not sever actin and the binding is reversible
based on Ca2+ levels (low levels reduce binding; ref. 15).
Macrophage capping protein is more abundant than gelsolin in
macrophages (15), and overexpression increases macrophage
phagocytic activity (28). Macrophage capping protein null mice
appear grossly normal and have normal numbers of neutro-
phils, lymphocytes, and mononuclear cells. Macrophage phago-
cytosis is decreased to about half that of normal mice. However,
despite this understanding of macrophage capping protein
function, this study suggests its first association with cancer. The
increase of macrophage capping protein may be a result of an
inflammatory reaction occurring in the cancerous lymph nodes,
quite possibly a direct reaction to the neoplastic cells.
Our results, finding an absence of triosephosphate isomerase
in most lymphoma cases, are in contrast with previous findings
of other investigators. Two-dimensional electrophoretic analy-
sis of lung adenocarcinoma revealed an increase of triosephos-
phate isomerase in 60% of adenocarcinomas compared with
uninvolved lung (29). Similarly, increased expression of
triosephosphate isomerase was found in lung squamous cell
carcinomas (30). Triosephosphate isomerase has also been
found to be increased in urinary cancers. Renal cell carcinoma
samples when compared with normal kidney cortex had
increased expression in all six samples tested (31). Possibly,
the down-regulation of triosephosphate isomerase in the
lymphoma samples represents an underlying cell type specific-
ity, but overall, it seems that misregulation of triosephosphate
isomerase is a common feature of cancer. Additional work will
be required to fully understand all these data and to elucidate
the mechanistic relationship between this enzyme and the
various forms of cancer.
There is a large literature on the roles of GST with respect to
cancer, and there is not a clear pattern (32). In addition to the
idea that the detoxifying activity of GST protects cells from
carcinogens, there are also reports that increases in GST are
correlated with increased resistance to chemotherapeutic drugs
and poor prognosis (33). Several studies clearly show an inverse
correlation between GST-P expression and cancer. In studies of
esophageal adenocarcinoma and ovarian cancer, the tumor
tissue showed lower GST-P levels in tumor tissue than in the
surrounding normal tissue (34, 35). The current studies on
canine lymphoma agree in that GST-P was observed more
frequently in the normal lymph nodes. This general pattern
supports the idea that loss of GST activity is associated with
tumor development.
In some cases, like with the GST and with the macrophage
capping protein, we identified protein spots that correspond to
these proteins but had lower than expected molecular weight.
Although it is entirely possible that these represent proteolytic
cleavage, it is important to mention that there is an increasing
literature on alternative splicing and its role in regulation of
cellular function (36). It will be interesting to analyze these genes
for possible alternative splice variants and to ascertain whether
these have a regulatory role in the onset or propagation of
lymphoma.
A possible drawback to using whole lymph node tissue is its
cellular heterogeneity (37). Tissues are composed of not only
the functional immune cells but also supporting structures,
Table 4. Identification of differentially regulated proteins
Protein name Synonyms Gene
name
Accession
no.
Molecular
weight
(kDa)
%
Coverage
Mowse
score
Normal
samples
Lymphoma
samples
Trioseposphate
isomerase
Phosphotriose
isomerase; triose
phosphoisomerase;
triosephosphate
isomerase;
triosephosphate
mutase
TIM P54714 26.7 72 74 9 of 13 1 of 11
Xaa-Pro
dipeptidase
g-Peptidase;
iminopeptidase;
peptidase D; proline
peptidase; X-Pro
dipeptidase;
EC 3.4.13.9
PEPD human P12955 54.5 32 67 8 of 13 0 of 11
Macrophage
capping
protein
Actin-regulatory
protein CAPG
LOC483082;
CAPG human;
MCP
P40121 38.5 49 121 3 of 13
(0 of 13 in
second group)
6 of 11
(5 of 11 in
second group)
GST-P GST7-7; EC 2.5.1.18 GST7-7 XP_532423 23.4 30 66 11 of 13 3 of 11
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such as connective tissue, blood vessels and blood cells, and
fat. Tumors are also heterogeneous and contain mixtures of
normal, transformed, and malignant cells, although in lym-
phomas nearly the entire lymph node is composed of
malignant cells. Despite these concerns, using lymph node
tissue allowed us to directly examine normal and tumor tissue
without any cell culture or cell fractionation and resulted in the
identification of the differentially expressed proteins.
Two-dimensional gel electrophoresis is widely available for
protein separation in proteomic studies and allows broad
proteomic analyses to be routinely done. The technique is
somewhat limited by sensitivity (10), but as can be seen in Figs. 1
and 2, a large number of proteins can be reproducibly separated
and displayed. This approach allowed us to compare, for the
first time, the proteomes of lymph nodes from normal dogs and
dogs with lymphoma. The discovery that GST, macrophage
capping protein, triosephosphate isomerase, and prolidase
were differentially expressed between the normal and cancerous
lymph nodes strongly supports the use of dogs as an effective
model for the study of malignancy. Other proteomic studies of
cultured cancer cells and tissues also have frequently identified
a relatively small set of differentially regulated proteins, which
may reflect the unique set of factors (e.g., sample type and
methods of protein separation and identification) involved in
the studies (38, 39). Thus, additional proteomic analyses of
canine tumors using other techniques are expected to provide the
identification of additional interesting markers that are expected
to be of value in both veterinary and human medicine.
This study represents an initial and necessary step needed to
identify markers that are differentially expressed between
normal and cancerous lymph nodes, which ultimately can
be used for diagnosis, staging, and monitoring of therapy. The
dog offered experimental advantages and should continue to be
useful in identifying more markers. Nevertheless, validation of
the identified protein markers by other techniques (e.g., ELISA-
based methods) in larger numbers of samples will be needed. In
addition, an examination of these markers in human lymphoma
samples will be an important goal. In this way, these and other
markers can be evaluated for their full potential for diagnosis
compared with currently used methods of histotyping. There is
the potential for these markers, once validated, to be routinely
measured in both veterinary and human clinical settings.
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